EDCtox

Mechanistic evidence atlas. Scores summarise biological direction and magnitude. They are not a toxicity rank or a human-risk number.

Compounds

Risperidone

Risperidone

Add to comparison
Category
pharmaceutical · Atypical antipsychotic
Record
specific compound · in current use
Identifiers
CAS 106266-06-2
Aliases
—

Atypical antipsychotic with a strong prolactin effect. Metabolic disruption is recorded as weaker than olanzapine in this seed.

Flags: pharmaceutical

Phase-1 numbers are seed hypotheses. They are not curated consensus, not a toxicity total, and not a statement of human risk. Association is not written as causation.

REP · Reproductive endocrinology

GnRH

GNRH · group HPG_AXIS · Hypothalamic–pituitary–gonadal axis · scorable

GnRH. Mechanism node for evidence linkage. A row here is not itself a finding.

Score +3Disruptive signalModerate confidenceH3seed hypothesisreview v1

GnRH suppression is downstream of prolactin in this seed and shares the HPG cluster.

Capped with prolactin. It does not raise REP from +4 to +7.

Phase-1 seed hypothesis, not a curated systematic review. Where a range was discussed, the stored integer is the conservative end closer to zero. A score is biological direction and magnitude, not human risk.

    No evidence finding is linked yet.

    Score history
    • 2026-10-03: — → +3. Initial seed hypothesis, version 1. Not a curated consensus.

    Prolactin

    PROLACTIN · group HPG_AXIS · Hypothalamic–pituitary–gonadal axis · scorable

    Prolactin secretion and signalling. Antipsychotic D2 antagonism can raise prolactin; that pharmacology is not the same as a metabolic effect.

    Score +4Disruptive signalHigh confidenceH4seed hypothesisreview v1

    Hyperprolactinemia is an established pharmacological effect at therapeutic doses.

    HPG-axis headline. This is not the metabolic comparison with olanzapine.

    Phase-1 seed hypothesis, not a curated systematic review. Where a range was discussed, the stored integer is the conservative end closer to zero. A score is biological direction and magnitude, not human risk.

      No evidence finding is linked yet.

      Score history
      • 2026-10-03: — → +4. Initial seed hypothesis, version 1. Not a curated consensus.

      DEV · Developmental endocrinology

      Puberty timing

      PUBERTY_TIMING · group PUBERTY · Puberty and growth · scorable

      Puberty timing. Mechanism node for evidence linkage. A row here is not itself a finding.

      Score +3Disruptive signalLow confidenceH2seed hypothesisreview v1

      Developmental seed at +3, mainly through prolactin and pubertal axis concern.

      Not a metabolic score.

      Phase-1 seed hypothesis, not a curated systematic review. Where a range was discussed, the stored integer is the conservative end closer to zero. A score is biological direction and magnitude, not human risk.

      • Developmental relevance uncertain

      No evidence finding is linked yet.

      Score history
      • 2026-10-03: — → +3. Initial seed hypothesis, version 1. Not a curated consensus.

      NEUROENDO · Neuroendocrine, HPA, and circadian

      Dopamine

      DOPAMINE · group DOPAMINE · HPA axis · scorable

      Dopamine. Mechanism node for evidence linkage. A row here is not itself a finding.

      Score +4Context-dependentHigh confidenceH4seed hypothesisreview v1

      Potent D2 antagonism is intended pharmacology and the driver of the prolactin effect.

      Neuroendocrine headline. Separate from insulin resistance.

      Phase-1 seed hypothesis, not a curated systematic review. Where a range was discussed, the stored integer is the conservative end closer to zero. A score is biological direction and magnitude, not human risk.

        No evidence finding is linked yet.

        Score history
        • 2026-10-03: — → +4. Initial seed hypothesis, version 1. Not a curated consensus.

        MET · Systemic metabolism

        Insulin resistance

        INSULIN_RESISTANCE · group INSULIN_SIGNALING · Insulin signalling pathway · scorable

        Impaired insulin action at target tissues. A mechanistic insulin-signalling change is not automatically a diagnosis of diabetes.

        Score +3Disruptive signalModerate confidenceH3seed hypothesisreview v1

        Exposure: therapeutic · adult · Adults prescribed risperidone

        Metabolic disruption is seeded at +3, below olanzapine's +4.

        Therapeutic-dose context. Not summed with prolactin.

        Phase-1 seed hypothesis, not a curated systematic review. Where a range was discussed, the stored integer is the conservative end closer to zero. A score is biological direction and magnitude, not human risk.

          No evidence finding is linked yet.

          Score history
          • 2026-10-03: — → +3. Initial seed hypothesis, version 1. Not a curated consensus.